GlassScriptPhysician profile
Jon N Burton
NPI 1790973808
$2,694.80
in general payments reported to CMS, 2019-2025
27 companies · $1,040 in 2025
The $1,040 reported for 2025 was more than what 80% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $151 · 2020: $96.16 · 2021: $126 · 2022: $540 · 2023: $439 · 2024: $302 · 2025: $1,040.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,748 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,747.68 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $559.01 | 2021-2025 | Dupixent |
| Optinose US, INC. | $488.40 | 2019-2025 | |
| Glaxosmithkline, LLC. | $417.76 | 2022-2025 | Nucala |
| Acclarent, INC | $234.15 | 2022-2023 | Trudi Nav Cable, Relieva Spinplus |
| Genzyme Corporation | $161.81 | 2022-2025 | |
| Depuy Synthes Sales INC. | $147.41 | 2025 | Matrixmandible |
| Intersect Ent, INC. | $120.09 | 2019-2020 | |
| Amgen INC. | $84.12 | 2025 | Tezspire |
| Smith+Nephew, INC. | $60.73 | 2020 | |
| Novartis Pharmaceuticals Corporation | $49.21 | 2025 | |
| Hikma Pharmaceuticals USA | $49.16 | 2022-2024 | Ryaltris |
| Stryker Corporation | $45.81 | 2022 | |
| Aerin Medical INC. | $34.60 | 2019-2024 | |
| Ambu INC. | $31.96 | 2021 | |
| Ars Pharmaceuticals Operations, INC. | $23.77 | 2025 | Neffy |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $22.18 | 2022 | |
| Merck Sharp & Dohme LLC | $20.93 | 2023 | |
| Genentech USA, INC. | $19.17 | 2022 | |
| Acera Surgical, INC. | $16.60 | 2022 | |
| Mimedx Group, INC. | $15.46 | 2025 | |
| Medtronic, INC. | $14.43 | 2025 | Propel |
| Neurent Medical Limited | $14.08 | 2023 | Neuromark Radiofrequency Console, Neuromark Device |
| Pfizer INC. | $13.76 | 2021 | |
| Hologic Sales and Service, LLC | $13.17 | 2022 | |
| Kaleo, INC. | $13.15 | 2020 | |
| Glenmark Therapeutics INC. | $12.00 | 2019 | |
| Phadia US INC. | $11.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jon Burton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.